$6.80
0.09 (+1.34%)
Exelixis, Inc. (EXEL)
CAPS Rating:
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
RSS Headlines
Fool UK
Recs
I am a molecular biologist and have been at presentations for mid/late stage compounds, such as PPAR ligands, that EXEL is developing. They have the expertise to develop successful compounds. And they are at a bargain basement price now. If you need a signal to enter, wait for insider buying, which hasn't occured lately as of 3/10/08.